Kevzara

Active Ingredient(s): Sarilumab
FDA Approved: * May 22, 2017
Pharm Company: * SANOFI SYNTHELABO
Category: Arthritis

Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor.[1] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.[2] Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Kevzara 150 mg/1.14ml Subcutaneous Injection, Solution

NDC: 0024-5908

Labeler:

Sanofi-aventis U.S. LLC

Kevzara 200 mg/1.14ml Subcutaneous Injection, Solution

NDC: 0024-5910

Labeler:

Sanofi-aventis U.S. LLC

Kevzara 150 mg/1.14ml Subcutaneous Injection, Solution

NDC: 0024-5920

Labeler:

Sanofi-aventis U.S. LLC

Kevzara 200 mg/1.14ml Subcutaneous Injection, Solution

NDC: 0024-5922

Labeler:

Sanofi-aventis U.S. LLC